Flashback http://www.streetinsider.com/dr/news.p
Post# of 72436
![](/assets/46931549/no_avatar_available_thumb.jpg)
http://www.streetinsider.com/dr/news.php?id=10796875
"As far as self-enrichment with CTIX, long-term shareholders know myself and Dr. Menon deferred our salaries for many years. We were working very hard to build the company without receiving a paycheck. Not only that, we loaned Cellceutix millions of dollars to help develop the company and its compounds when no other financing options were available. This can be seen in SEC filings for the years 2008-2011. Our spouses thought we were nuts, but we were on -- and remain on -- a mission to develop our drugs."
"Cellceutix has a robust pipeline with a full slate of ongoing and planned clinical trials. Our goal is to be the next Regeneron (REGN), a company built on novel science with the vision and strategy to grow exponentially."
"If one takes a moment to analyze our growth since we began to work with Aspire Capital in December 2012, when shares of CTIX were around $1.20 each, it is easy to see how their investment has provided us with the resources to grow our company and build shareholder value. In three years, shares are still ahead from that point, in spite of numerous, less-than-credible attacks on the Cellceutix in recent years, including this last one."
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)